Delving into the Latest Updates on IPM-001 with Synapse

Overview

Basic Info

Drug Type

Cell therapy

Synonyms

Target-

Mechanism

Immunostimulants

Therapeutic Areas

NeoplasmsDigestive System Disorders

Active Indication

Hepatocellular Carcinoma

Inactive Indication-

Originator Organization

Beijing Zhenzhi Medical Technology Co., Ltd.Startup

Active Organization

Shanghai Huashan Hospital

Beijing Zhenzhi Medical Technology Co., Ltd.Startup

Inactive Organization-

Drug Highest PhaseEarly Phase 1

First Approval Date-

Regulation-

Login to view timeline

Vaginal delivery of 200 mg or 25 mg dapivirine from intravaginal rings (IVRs) was evaluated over a 7-day period in two phase 1 safety trials (IPM001 and IPM008, respectively) in a total of 25 healthy women 19 to 46 years of age. The IVR was generally safe and well tolerated with similar adverse events observed in the placebo and dapivirine groups. Across both studies, dapivirine concentrations in vaginal fluids measured at the introitus, cervix, and ring area were within the mean range of 0.7-7.1 microg/ml. Mean dapivirine concentrations in vaginal and cervical tissues on day 7 were 0.3-0.7 microg/g in IPM001 and 1.5-3.5 microg/g in IPM008. Mean plasma concentrations of dapivirine were <50 pg/ml. Dapivirine from both IVRs was successfully distributed throughout the lower genital tract at concentrations >1000x the EC(50) against wild-type HIV-1 (LAI) in MT4 cells suggesting that IVR delivery of microbicides is a viable option meriting further study.

100 Deals associated with IPM-001

Login to view more data

R&D Status

10 top R&D records.

Login

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Hepatocellular Carcinoma	Phase 1	CN	Beijing Zhenzhi Medical Technology Co., Ltd.Startup	31 Dec 2021
Hepatocellular Carcinoma	Phase 1	CN	Shanghai Huashan Hospital	31 Dec 2021